- Home
- SYT vs CASI Comparison
SYT vs CASI Comparison
Compare SYT & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYT
- CASI
- Stock Information
- Founded
- SYT 2010
- CASI 1991
- Country
- SYT Japan
- CASI China
- Employees
- SYT N/A
- CASI N/A
- Industry
- SYT Real Estate
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- SYT Finance
- CASI Health Care
- Exchange
- SYT Nasdaq
- CASI Nasdaq
- Market Cap
- SYT 41.2M
- CASI 33.4M
- IPO Year
- SYT 2023
- CASI 1996
- Fundamental
- Price
- SYT $1.99
- CASI $2.10
- Analyst Decision
- SYT
- CASI Strong Buy
- Analyst Count
- SYT 0
- CASI 1
- Target Price
- SYT N/A
- CASI $6.00
- AVG Volume (30 Days)
- SYT 6.7K
- CASI 8.5K
- Earning Date
- SYT 04-08-2025
- CASI 03-31-2025
- Dividend Yield
- SYT 0.31%
- CASI N/A
- EPS Growth
- SYT N/A
- CASI N/A
- EPS
- SYT 0.08
- CASI N/A
- Revenue
- SYT $149,124,408.00
- CASI $28,537,000.00
- Revenue This Year
- SYT N/A
- CASI N/A
- Revenue Next Year
- SYT N/A
- CASI $134.79
- P/E Ratio
- SYT $25.86
- CASI N/A
- Revenue Growth
- SYT 3.11
- CASI N/A
- 52 Week Low
- SYT $1.18
- CASI $2.04
- 52 Week High
- SYT $6.10
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- SYT 53.20
- CASI 42.35
- Support Level
- SYT $1.96
- CASI $2.10
- Resistance Level
- SYT $2.05
- CASI $2.52
- Average True Range (ATR)
- SYT 0.08
- CASI 0.21
- MACD
- SYT -0.01
- CASI 0.00
- Stochastic Oscillator
- SYT 62.70
- CASI 12.50
About SYT SYLA Technologies Co. Ltd.
SYLA Technologies Co Ltd is a property technology company. It provides asset management platform systems that facilitate real estate crowd-funding as well as the purchase and sale of real estate.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.